Aytu BioScience (AYTU) – Press Releases
-
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
-
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now
-
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
-
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
-
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
-
Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now
-
Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
-
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
-
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year
-
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023
-
Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
-
Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023
-
Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023
-
Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023
-
Aytu BioPharma to Present at LD Micro Main Event XVI Conference
-
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
-
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority
-
Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
-
Aytu to Participate in the Maxim Group Virtual Healthcare Conference
-
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market
-
Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director
-
Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results
-
Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023
-
Aytu BioPharma Subleases a Portion of Its Manufacturing Facility
-
Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer
-
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023
-
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023
-
Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results
-
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023
-
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance
-
Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31
-
Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients
-
Aytu BioPharma Announces 1-for-20 Reverse Stock Split
-
Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect
-
Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
-
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row
-
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso
-
Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023
-
Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022
-
Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company's Term Loan
-
Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs
-
Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT(R) in Response to Reported Generic Adderall(R) XR Supply Disruptions
-
Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue
-
Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022
-
Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin
-
Aytu BioPharma to Participate in September 2022 Investor Conferences
-
Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
-
Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering
-
Aytu BioPharma Announces Pricing of Public Offering
-
Aytu BioPharma Announces Launch of Public Offering
Back to AYTU Stock Lookup